Bibliografía: Abbas, AK., et al. Cellular and molecular immunology. Elsevier. 9th edition. 2018 https://t.co/EbnRP0aMgM https://t.co/p4W665XqEQ https://t.co/avJrnPzH2W https://t.co/QpvapTW4RT https://t.co/2vmf77spIN https://t.co/kzFQKAxxaq https://t.c
"immunogenicity of a novel chimpanzee adenovirus-vectored vaccine, #ChAdOx1 nCoV-19 (#AZD1222)"
RT @LuisZuritaG: Vacuna contra SARS Cov2 : esta vacuna usa como vector un adenovirus, y utilizando dosis baja, y luego la standar, su efica…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/R410MKNlyl
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/tmT1aLzo1X
@95thoughts @halvorz @DeadLiftCapital this is from earlier phase 2/3 paper https://t.co/dpbBj99jJA https://t.co/N5rMtNbr7J
Vacuna ChAdOx1 (Oxford y AstraZeneca) Fase 2/3 (560 pacientes) https://t.co/1GakxSnI4E https://t.co/XkPzcMFmk5
@Tob11tob116 @noMasknoShot @M_T_Franz Fakten gibt’s zu Hauf in Fachjournals (z B hier) https://t.co/X2f7285CNq Müsste man sich halt damit befassen. Und jeder aus der „verunsicherten Bevölkerung“ kann sich nach Zulassung des Impfstoffs den Beipackzettel dur
@stuart_dandro @Coronavirusgoo1 Based on the most recent paper, it seems they were spaced 28 days apart in the trial https://t.co/bLeXRcjiBq
Oxford-AstraZeneca scheint bei älteren Erwachsenen besser verträglich zu sein als bei jüngeren Erwachsenen und weist nach einer Boost-Dosis eine ähnliche Immunogenität in allen Altersgruppen auf. https://t.co/oCrQ72DzfM
Sale el estudio fase 2/3 con seguridad e inmunogenicidad, el cual incluye mayores de 70 años. https://t.co/X1gzHfuaey
@KaremAedoGonzal @Aleciiita @RinconSalfate Podría mandarme ese Paper? El último que leí sobre vacunas en esa revista fue la de Oxford y no muestra lo que has dicho. Si bien no se sabe si estas personas pueden contagiar, no hay datos de ello, ni que hayan p
@TalbertSwan @TanteJay Yes there has. There are around 5000 seperate studies listed on PubMed for Covid vaccines. Heres some of them AstroZeneca's one;- https://t.co/qasVTDbkAz
Participants aged 65 and older with Clinical Frailty Score of 4 or higher excluded, median age of "older" people only 73 in @TheLancet ChAdOx1 nCoV-19 vaccine trial in young and "old" adults https://t.co/86LFa5NC1d - unrepresentative of those most at risk
@faktuellt @Sven_Roman @someuse @AgnesWold Bland personer överlag utan underliggande sjukdomar då. https://t.co/DsyX9he9gw "the selection of participants aged 70 years and older, with a median age of 73–74 years between dose groups and with few comorbidit
RT @LuisZuritaG: Vacuna contra SARS Cov2 : esta vacuna usa como vector un adenovirus, y utilizando dosis baja, y luego la standar, su efica…
RT @LuisZuritaG: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002…
RT @LuisZuritaG: Vacuna contra SARS Cov2 : esta vacuna usa como vector un adenovirus, y utilizando dosis baja, y luego la standar, su efica…
RT @LuisZuritaG: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002…
Vacuna contra SARS Cov2 : esta vacuna usa como vector un adenovirus, y utilizando dosis baja, y luego la standar, su eficacia iguala a Pfizer. De comprobarse resultados su distribución globsl sería más fácil
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/fbMOzWGBwT
@DocBastard I would add this one: https://t.co/r9wA38R146
Os regimes de dose da AstraZeneca contemplam 2 doses, com dois regimes diferentes que foram apresentados, na fase 3. https://t.co/Eg5E8xLAfh
31/n Another study on the Astra Zeneca vaccine in older adults: "160 aged 56–69 years (120 assigned to ChAdOx1 nCoV-19: 40 assigned to MenACWY), and 240 aged 70 years and older (200 assigned to ChAdOx1 nCoV-19..." https://t.co/GYTnIggLtF
@AlexBerenson They used the meningitis vaccine for the "placebo" so that it would make the serious adverse events look similar to those in "placebo". https://t.co/4GC8hUjGDQ
@GHounmanou But the oxford vaccine does show an immunological response in >70 year old and most likely vaccine candidate for regions without -70ºC storage. https://t.co/j2M7UffBPm
@NBCNews In this AstraZeneca/Oxford Univ. C19 study, they are not using real (saline-)placebos, but a "MenACWY-vaccine" (meningococcus) for the control group. 😳 this is science fraud! https://t.co/pWIxpqvH3d
That Lancet paper is about the Oxford/AstraZeneca vaccine ChAdOx1, not Pfizer's
@DNABARCODE @megtirrell Hi expert Gitte! Can you help me out? What placebo was given? Saline or MenACWY? Page 4 (Randomisation and masking) at https://t.co/hsjUxxAiP1 https://t.co/LbSkrZQ2xO
@CMichaelGibson Michael, Nov 19/2020 the placebo was NOT just saline 🧐 https://t.co/4fJzH86f2O
@hapelensrob Rob, wat gebruikte Pfizer als ‘placebo’? Saline of een ‘meningococcal’ vaccin? I’m confused... https://t.co/oS9943w5AT
@GrahamLawton Hi Graham, it’s me again 😏 Look what I found: Nov 19/2020: “MenACWY was used as a comparator vaccine rather than a saline placebo to maintain masking of participants who had local or systemic reactions.” Source: https://t.co/hsjUxxAiP1 Whe
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/kbHzUdSY7t
Any company that applies for approval for a new drug/vaccine has to make its data public. The data is given to regulators, and published in scientific journals (where academic experts analyze the details and give their opinions). For ex, Oxford vaccine: ht
A useful analysis of Lancet peer-review of the AstraZenica/Oxford vaccine. Review: https://t.co/3KzGj1jK4t Comment: https://t.co/mZmvnX3Hqe A 32-minute video by Dr. John Campbell (I watched it at 1.5x speed). "First peer-reviewed vaccine evidence" http
@StefanoMarw Tuttavia è più una panoramica generale sui vaccini e non entra troppo nel merito dell’efficacia e della sicurezza di ChAdOx1 o di Pfizer, su cui arriveranno, immagino, novità a breve. A proposito, questo su AstraZeneca è uscito qualche settima
RT @earthrouter: @de2_0 @Ironieuse England: In dieser Studie eines AstraZeneca/Oxford Univ. C19-Impfstoffs verzichtet man mittlerweile ganz…
@de2_0 @Ironieuse England: In dieser Studie eines AstraZeneca/Oxford Univ. C19-Impfstoffs verzichtet man mittlerweile ganz auf "saline placebo"! Stattdessen benutzt man ein "MenACWY-vaccine" für die Kontrollgruppe, also ein Meningokokken-vaccine. Hasardeur
@RealCandaceO The AstraZeneca/Oxford Univ. C-19 vaccine does not use "saline placebo" in the control group, but MenACWY-vaccine (Meningococcal)!! This is incredible. 😳 https://t.co/pWIxpqvH3d
@reitschuster @Tiffy052 In dieser Studie eines AstraZeneca/Oxford Univ. C19-Impfstoffs verzichtet man mittlerweile ganz auf "saline placebo"! Stattdessen benutzt man ein "MenACWY-vaccine" für die Kontrollgruppe, also ein Meningokokken-vaccine. Unglaublich.
In dieser Studie eines AstraZeneca/Oxford Univ. C19-Impfstoffs verzichtet man mittlerweile ganz auf "saline placebo"! (Kochsalzlösung) Stattdessen benutzt man ein "MenACWY-vaccine" für die Kontrollgruppe, also ein Meningokokken-vaccine. Unglaublich. 😳 http
@OliverJanich Oli, in dieser Studie eines AstraZeneca/Oxford Univ. Impfstoffs hat man sogar ganz verzichtet auf Kochsalzlösung- "saline placebo"! Stattdessen benutzt man ein "MenACWY-vaccine" für die Kontrollgruppe, also ein Meningokokken-vaccine. Unglaubl
@Summertimeblu20 @OliverJanich Halt-die-Frxxxx! in dieser Studie eines AstraZeneca/Oxford Univ. Impfstoffs hat man sogar ganz verzichtet auf "saline placebo"! Stattdessen benutzt man ein "MenACWY-vaccine" für die Kontrollgruppe, also ein Meningokokken-vac
Aucune donnée immunologique n’existe pour ces schémas avec des doses mixtes https://t.co/Hy4R2UUKB6
RT @MaxCRoser: New results from the Oxford vaccine trial just got published in The Lancet. It studied whether the immune response provoked…
@DaisyDu34255524 @JonBelh @Latlanh86 @Delrane @Acermendax @Asclepios_YT @docprimum @nathanpsmad @Damkyan_Omega Bon finalement la réponse était assez facile à trouver. Voici l'explication du protocole page 115 https://t.co/Ng3V6i5WjM https://t.co/2xEgpoFrnJ
Reassuring to know that such a prominent journalist has read the journal article to find the answer to this question before tweeting, or has at least read the abstract. Oh wait... https://t.co/pTk9o2m3QQ
@boyandthedog Faza 2 za Oxford-AZ: https://t.co/6lFggKEhji
@wszczeklik @faktypofaktach Kiepskie wyniki testow szczepionki oksfordzkiej. Okazuje sie, ze wsrod probantow nie bylo osob 50+. https://t.co/7869FxfYh6
@SineQuaNon2015 Πρώτη η AstraZeneca δημοσίευσε επίσημα τα δεδομένα της φάσης 2 και 3 για το δικό της εμβόλιο στο Lancet. Μόλις δημοσιεύσουν και οι Pfizer κι η Moderna θα σου τα στείλω... https://t.co/hk1IxZKs1d
Däremot har AstraZeneca i sin tidigare studie studerat lågdos- kontra högdosdosering (bägge i två doser). De fann då att bägge doseringar gav samma immunsvar 28 dagar efter andra dosen. Andra dosen gav en tydlig boost i immunsvaret på vaccinet: https://t.
Safe and better tolerated in older adults. Next is efficacy, also for chronic patients #COVID19Vaccine #COVID19 #oxfordvaccine https://t.co/YLDQpEzexr
And if you worry about side-effects (and there will be some) details here https://t.co/4lu66i72ba
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial - The Lancet https://t.co/s73VRK2KsS
RT @PriyankaPulla: Preliminary analysis from Oxford-Astrazeneca trial is published. Turns out there were two cases of transverse myelitis i…
@_b_meyer
Confirmation in peer-reviewed journal that Oxford #COVID19Vaccine works well https://t.co/om13LMD62O
RT @PriyankaPulla: Preliminary analysis from Oxford-Astrazeneca trial is published. Turns out there were two cases of transverse myelitis i…
RT @PriyankaPulla: Preliminary analysis from Oxford-Astrazeneca trial is published. Turns out there were two cases of transverse myelitis i…
@EricTopol @TheLancet @AstraZeneca @UniofOxford your link doesn’t work for me. at this link for the paper, I can’t find the info on asymptomatic infections to which you linked: https://t.co/USv6xGVnCk the data on the efficacy against asymptomatic infectio
Preliminary analysis from Oxford-Astrazeneca trial is published. Turns out there were two cases of transverse myelitis in the vaccine arm, and one in control. https://t.co/mlJeFxPHu3
@Hallaschka_HH @PanPagan @CarstenWack @Roman05171047 1. Der Impfstoff von Biontech/Pfizer ist der weltweit erste RNA-Impfstoff überhaupt, der eine Zulassung erhält. 2. Alle 3 Phasen der Studien sind gegenüber normalen Zulassungsverfahren erheblich verkürzt
RT @fagstein: @RebeccaSharratt The vaccine trials are being reviewed by several teams of experts, including a group at the WHO, and panels…
RT @fagstein: @RebeccaSharratt The vaccine trials are being reviewed by several teams of experts, including a group at the WHO, and panels…
@RebeccaSharratt The vaccine trials are being reviewed by several teams of experts, including a group at the WHO, and panels at Health Canada and similar boards in countries around the world. You can see an example of a study here https://t.co/lSJrSqpyRr
This is worth a read.
@SakuSolberg @zirkkeli1 @RikkinenSirpa @OssiTiihonen Täällä on samasta rokotteesta tehtynä tuore tutkimus ihmisillä, jossa 560 osallistujaa: https://t.co/QzUsFttqNg Tämän jälkeen tarvitaan vielä tuhansien tai kymmenien tuhansien ihmisten turvallisuustutki
@TatayoyoKesski1 Sans doute la réponse dans le protocole : ils ont recruté d'abord les sujets jeunes, puis les sujets aĝés après une revue de safety. Ceci signifie que ces données sont prévues, mais retardées pour cette raison. https://t.co/Ng3V6i5WjM http
RT @chayito09: Laboratory-Scale Production of Replication-Deficient Adenovirus Vectored Vaccines Susan J. Morris, Alison V. Turner, Nicola…
De la Science, que de la Science...
RT @T_Fiolet: Novavax, phase I-II : https://t.co/m32T3EyTW6 ARNm-1273 Moderna phase I : https://t.co/pBfp4pP2py Moderna phase I >55 ans :…
RT @T_Fiolet: Novavax, phase I-II : https://t.co/m32T3EyTW6 ARNm-1273 Moderna phase I : https://t.co/pBfp4pP2py Moderna phase I >55 ans :…
@galleguiceitor el parrafo que te puse es un corta-pega. Vamos a los papers https://t.co/MGXUKb3jLp
@galleguiceitor Aqui tienes la de Oxford https://t.co/MGXUKb3jLp
@JohnDee63999880 @ronan_glynn @HSEImm @RCPI_news As requested https://t.co/oAup8O2B0O
Κατασκευαζει ανασυνδυασμενο dna .. δηλαδη που περιεχει γονιδια απο δυο διαφορετικα ειδη... στο μελλον θα γινουμε ΧΜΕΝ ? https://t.co/MenKlUPdrG
RT @J_B_oo7: @Karl_Lauterbach Ich wusste ja, dass Sie hart mit Ihren persönlichen Einschränkungen zu kämpfen haben. Aber das Sie weder THE…
@Sharonlevinson2 @LittleMoiz @RackMada @florian_krammer כל החברות מפרסמות בדרך קבע את התוצאות בג'ורנלים מדעיים. אסטרא זנקא פרסמו תוצאות ביניים שלב 3 לפני כמה שבועות:https://t.co/ivbfs3Kbc5 לא ראיתי פרסום של J&J אבל יכול להיות שסתם פספסתי.
@bluepearl555 @monika39663262 Jeśli zada Pan sobie trud przeczytania poniższego artykułu, to Pańskie "wydaje mi się" okaże się niepoważną mrzonką. Proszę czytać coś więcej niż własne myśli, wtedy nie będzie Pan musiał bazować na własnych, dalekich od praw
RT @JuanjoArm: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002):…
Excelente explicación. Muchas gracias.
RT @chayito09: Laboratory-Scale Production of Replication-Deficient Adenovirus Vectored Vaccines Susan J. Morris, Alison V. Turner, Nicola…
RT @chayito09: Laboratory-Scale Production of Replication-Deficient Adenovirus Vectored Vaccines Susan J. Morris, Alison V. Turner, Nicola…
RT @hildabast: @LeaozinhoM @ellis_muggleton @TranspariMED @schneiderleonid @RIATinitiative @Dereklowe You can see all of them here: https:/…
Así debieran ser TODAS las publicaciones en cada red social.
Laboratory-Scale Production of Replication-Deficient Adenovirus Vectored Vaccines Susan J. Morris, Alison V. Turner, Nicola Green, and George M. Warimwe. Chapter 8. https://t.co/CoiN59BLbW https://t.co/wYDNLRCII7 https://t.co/avJrnPzH2W https://t.co/kzF
Publication sur le ChAd0x1 https://t.co/QnOJ4heGgG
@LeaozinhoM @ellis_muggleton @TranspariMED @schneiderleonid @RIATinitiative @Dereklowe You can see all of them here: https://t.co/M10e2Gf6Ib The one for the UK phase 2/3 trial for the Oxford vaccine is in this appendix https://t.co/SBCuAhrh5x
RT @JuanjoArm: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002):…
Novavax, phase I-II : https://t.co/m32T3EyTW6 ARNm-1273 Moderna phase I : https://t.co/pBfp4pP2py Moderna phase I >55 ans : https://t.co/SEfPRmz32L Pfizer phase I/II : https://t.co/IELo13SWV6 Pfizer : https://t.co/AzWopoj7wj Astrazeneca : https://t.co
RT @JuanjoArm: Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002):…
Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial https://t.co/COOFBnWrh9